Tang Yu, Qu Jintao, Wu Juan, Li Song, Zhou Yue, Xiao Jianru
Department of Orthopaedic Surgery, Affiliated Xinqiao Hospital, The Third Military Medical University, No. 2, Xinqiao Street, Shapingba District, Chongqing 400037, People's Republic of China. E-mail address for Y. Zhou:
Department of Orthopaedic Surgery, No. 44 Military Hospital, No. 67 Huang He Road, Xiao He District, Guiyang, Guizhou 550009, People's Republic of China.
J Bone Joint Surg Am. 2015 Sep 2;97(17):1418-25. doi: 10.2106/JBJS.N.01124.
Metastatic spinal cord compression is a disastrous consequence of non-small-cell lung cancer (NSCLC). There have been few studies of the outcomes or prognostic factors in patients with metastatic spinal cord compression from NSCLC treated with surgery and adjuvant therapies.
From 2002 to 2013, 116 patients with metastatic spinal cord compression from NSCLC treated with surgery and adjuvant therapies were enrolled in this retrospective analysis. Kaplan-Meier methods and Cox regression analysis were used to estimate overall survival and identify prognostic factors for survival.
Multivariate analysis suggested that the Eastern Cooperative Oncology Group performance status (ECOG-PS), preoperative and postoperative Frankel scores, postoperative adjuvant radiation therapy, and target therapy were independent prognostic factors. Ninety patients died at a median of twelve months (range, three to forty-seven months) postoperatively, and twenty-six patients were still alive at the time of final follow-up (at a median of fifteen months [range, five to fifty-four months]).
The complete disappearance of deficits in spinal cord function after surgery was the most robust predictor of survival. Adjuvant radiation therapy and target therapy were also associated with a better prognosis.
Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
转移性脊髓压迫症是非小细胞肺癌(NSCLC)的灾难性后果。关于接受手术及辅助治疗的NSCLC转移性脊髓压迫症患者的预后或预后因素的研究较少。
2002年至2013年,116例接受手术及辅助治疗的NSCLC转移性脊髓压迫症患者纳入本回顾性分析。采用Kaplan-Meier法和Cox回归分析评估总生存期并确定生存的预后因素。
多因素分析表明,东部肿瘤协作组体能状态(ECOG-PS)、术前及术后Frankel评分、术后辅助放疗和靶向治疗是独立的预后因素。90例患者术后中位12个月(范围3至47个月)死亡,26例患者在最后随访时仍存活(中位15个月[范围5至54个月])。
术后脊髓功能缺损完全消失是生存的最强有力预测因素。辅助放疗和靶向治疗也与较好的预后相关。
预后IV级。有关证据水平的完整描述见作者须知。